Key result
Tailoring NOAC selection by clinical profile optimizes stroke prevention and bleeding risk in high-risk AF.
Why the study?
Managing AF in special, high-risk populations presents unique clinical challenges that require careful consideration to identify the optimal anticoagulation strategy.
How should non-vitamin K antagonist oral anticoagulants be selected for stroke prevention in high-risk patients with atrial fibrillation based on patient profiles?
How should non-vitamin K antagonist oral anticoagulants be selected for stroke prevention in high-risk patients with atrial fibrillation based on patient profiles?
Personalizing NOAC therapy based on patient comorbidities and age is crucial for optimizing stroke prevention and minimizing bleeding risks in atrial fibrillation.
May support tailored NOAC selection in high-risk AF; leaves open need for prospective validation before practice change.
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations, including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
No takes yet. Share an insight, caveat, or question.
Ton et al. (2023) conducted a review in Atrial Fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (e.g., warfarin) was evaluated. Tailoring non-vitamin K antagonist oral anticoagulants based on specific clinical profiles (e.g., renal impairment, diabetes, advanced age) optimizes stroke prevention and minimizes bleeding risks in high-risk atrial fibrillation patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: